Projected Income Statement: DaShenLin Pharmaceutical Group Co., Ltd.

Forecast Balance Sheet: DaShenLin Pharmaceutical Group Co., Ltd.

Forecast Balance Sheet - DaShenLin Pharmaceutical Group Co., Ltd.
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt 1 -469 -1,352 -990 -1,373 -3,236 -3,319 -3,743 -4,030
Change - -188.27% 26.78% -38.69% -135.69% -2.57% -12.77% -7.67%
Announcement Date 4/27/22 4/27/23 4/28/24 4/25/25 4/23/26 - - -
1CNY in Million
Estimates

Cash Flow Forecast: DaShenLin Pharmaceutical Group Co., Ltd.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
CAPEX 1 1,273 997.4 1,782 1,447 455.5 579 954.3 1,030
Change - -21.67% 78.66% -18.78% -68.53% 27.12% 64.83% 7.9%
Free Cash Flow (FCF) 1 281.7 2,759 1,392 1,659 4,895 1,775 2,800 3,241
Change - 879.62% -49.56% 19.2% 195.04% -63.74% 57.79% 15.75%
Announcement Date 4/27/22 4/27/23 4/28/24 4/25/25 4/23/26 - - -
1CNY in Million
Estimates

Forecast Financial Ratios: DaShenLin Pharmaceutical Group Co., Ltd.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) 14.37% 8.86% 8.64% 12.81% 13.94% 12.03% 12.54% 12.64%
EBIT Margin (%) 6.21% 6.69% 6.65% 5.66% 7.41% 8.15% 8.13% 8.39%
EBT Margin (%) 6.23% 6.66% 6.64% 5.06% 6.72% 7.57% 7.84% 8.11%
Net margin (%) 4.72% 4.87% 4.76% 3.45% 4.49% 5.11% 5.29% 5.44%
FCF margin (%) 1.68% 12.99% 5.67% 6.26% 17.8% 6% 8.61% 9.04%
FCF / Net Income (%) 35.6% 266.4% 119.32% 181.36% 396.25% 117.55% 162.72% 166.21%

Profitability

        
ROA 5.33% 5.43% 5.07% 3.5% 4.67% 5.46% 6.13% 6.6%
ROE 14.61% 17.87% 18.01% 13.17% 17.16% 19.65% 20.83% 22.54%

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 7.6% 4.69% 7.26% 5.46% 1.66% 1.96% 2.93% 2.87%
CAPEX / EBITDA (%) 52.88% 52.98% 84.09% 42.62% 11.88% 16.28% 23.41% 22.73%
CAPEX / FCF (%) 452.09% 36.15% 128.03% 87.24% 9.31% 32.63% 34.08% 31.77%

Items per share

        
Cash flow per share 1 1.365 3.298 2.787 2.728 4.698 4.99 4.175 4.82
Change - 141.59% -15.51% -2.12% 72.24% 6.22% -16.33% 15.45%
Dividend per Share 1 0.3472 0.5 0.31 0.31 0.49 0.9482 1.046 1.227
Change - 44% -38% 0% 58.06% 93.51% 10.29% 17.32%
Book Value Per Share 1 4.643 5.287 5.992 6.056 6.47 6.829 7.486 8.036
Change - 13.87% 13.32% 1.08% 6.82% 5.55% 9.62% 7.35%
EPS 1 0.6944 0.9083 1.03 0.81 1.08 1.33 1.502 1.697
Change - 30.8% 13.39% -21.36% 33.33% 23.11% 12.96% 12.96%
Nbr of stocks (in thousands) 1,138,968 1,138,947 1,138,902 1,138,848 1,138,848 1,138,879 1,138,879 1,138,879
Announcement Date 4/27/22 4/27/23 4/28/24 4/25/25 4/23/26 - - -
1CNY
Estimates
2026 *2027 *
P/E 15.5x 13.7x
PBR 3.01x 2.75x
EV / Sales 0.68x 0.61x
Yield 4.61% 5.08%

EPS & Dividend

EPS & Dividend - DaShenLin Pharmaceutical Group Co., Ltd.


Y-o-Y evolution of P/E

Valuation ratios - P/E - DaShenLin Pharmaceutical Group Co., Ltd.
 

Year-on-year evolution of the Yield

Valuation ratios - Yield - DaShenLin Pharmaceutical Group Co., Ltd.
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - DaShenLin Pharmaceutical Group Co., Ltd.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
20.58CNY
Average target price
24.02CNY
Spread / Average Target
+16.74%
  1. Stock Market
  2. Stocks
  3. 603233 Stock
  4. Financials DaShenLin Pharmaceutical Group Co., Ltd.